Why Japan is Rethinking Tobacco Alternatives
The Growing Cost of Healthcare
Japan has always been known for having an excellent healthcare system, but lately, costs have been going up, putting a strain on hospitals and resources. The reason? An aging population and expensive medical treatments. By 2060, the average life expectancy will hit 85 for men and 91 for women, meaning more people needing medical care for longer. The potential impact of these demographic shifts is immense, as Japan’s healthcare system must adapt to rising demands while managing financial sustainability (Mahlich and Kamae, 2024).
One major contributor to rising healthcare costs is smoking-related illnesses. Diseases like lung cancer, stroke, heart disease, and COPD require expensive treatments and long hospital stays, adding pressure to an already stretched healthcare system (Thun et al., 2000; Gandini et al., 2008).
Japan has tried various methods to get people to quit smoking, but success has been limited. Only 25 percent of smokers actually want to quit (Ministry of Health, Labour and Welfare, 2019). This means that simply banning cigarettes isn’t the answer—there needs to be a practical alternative for smokers who don’t want to quit but still need a safer option.
Can Heated Tobacco Products Help?
This is where heated tobacco products (HTPs) come in. Unlike traditional cigarettes, HTPs heat tobacco instead of burning it, which reduces the number of harmful chemicals released. According to studies, switching from cigarettes to HTPs can cut toxic exposure by up to 70 percent (Forster et al., 2017; Bekki et al., 2017).
If half of Japan’s smokers switched to HTPs, the country could see: ✔ 12 million fewer cases of smoking-related illnesses every year (Mahlich and Kamae, 2024). ✔ JPY 454 billion in healthcare savings (Mahlich and Kamae, 2024). ✔ Less strain on hospitals and medical professionals (Ministry of Health, Labour and Welfare, 2022).
With numbers like these, HTPs could be a practical solution for reducing smoking-related healthcare costs in Japan.
Potential Impact: Understanding Heated Tobacco Products and Their Role in Harm Reduction
What Makes HTPs Different from Cigarettes?
HTPs are designed to give smokers an alternative without forcing them to quit completely. Instead of burning tobacco like regular cigarettes, HTPs heat it at lower temperatures, which helps cut down on toxic emissions and harmful chemicals (Mahlich and Kamae, 2024).
There are currently four major brands in Japan offering HTPs, and each one uses different heating technology to make sure the tobacco produces less harmful smoke (Bekki et al., 2017).
Potential Impact: Why HTPs Are Considered Less Harmful
Research shows that HTPs expose users to significantly fewer toxic chemicals than cigarettes. Some key findings include: ✔ 97 percent fewer toxicants compared to cigarettes (Forster et al., 2017). ✔ 80 percent fewer harmful emissions, lowering health risks (Li et al., 2019). ✔ Less carbon monoxide exposure, helping improve heart health (Zhang et al., 2024).
Additionally, HTP users tend to smoke fewer sticks per day than regular cigarette smokers, meaning they are getting lower doses of nicotine and harmful substances overall (Sutanto et al., 2020).
How Japan’s Public Health Policies Can Support HTP Adoption
Japan has traditionally focused on encouraging people to quit smoking entirely, but since many smokers do not want to quit, experts argue that harm reduction strategies should be prioritized (Ministry of Health, Labour and Welfare, 2019).
For HTPs to work effectively as a harm-reduction tool, policymakers could: ✔ Educate smokers on the benefits of switching to lower-risk products (Mahlich and Kamae, 2024). ✔ Adjust taxation policies to make HTPs more affordable (Ministry of Health, Labour and Welfare, 2022). ✔ Introduce regulations that recognize HTPs as a separate category from cigarettes, acknowledging their reduced risks (Djurdjevic et al., 2018).
Japan’s approach needs to shift from banning cigarettes to offering safer alternatives, giving smokers a realistic option to reduce their health risks while still maintaining their autonomy.
The Potential Impact on Smoking-Related Diseases
The Serious Health Risks of Smoking
Smoking has long been linked to life-threatening diseases, making it one of the biggest public health concerns in Japan. It increases the chances of developing chronic obstructive pulmonary disease (COPD), ischemic heart disease (IHD), stroke, and lung cancer (Mahlich & Kamae, 2024). These diseases don’t just affect smokers—they also lead to higher healthcare costs, strain hospital resources, and reduce overall quality of life.
- COPD: Smoking damages lung tissue, making it harder to breathe. Over time, people with COPD struggle with daily activities due to shortness of breath (Thun et al., 2000).
- Ischemic Heart Disease: Cigarettes cause plaque buildup in arteries, leading to heart attacks and heart disease (Gandini et al., 2008).
- Stroke: Smoking raises blood pressure and weakens blood vessels, increasing the likelihood of strokes and brain damage (Mahlich & Kamae, 2024).
- Lung Cancer: The toxic chemicals in cigarette smoke significantly increase cancer risks, making lung cancer one of the deadliest diseases linked to smoking (Bekki et al., 2017).
Japan has strict tobacco control policies, but quitting smoking remains a challenge for many. Since only 25 percent of smokers actually want to quit (Ministry of Health, Labour and Welfare, 2019), policymakers are looking into harm reduction strategies like heated tobacco products (HTPs).
Potential Impact: How Switching to HTPs Could Reduce Smoking-Related Patients
Research shows that HTPs produce fewer harmful chemicals than traditional cigarettes, lowering the risk of smoking-related illnesses (Forster et al., 2017). Some key findings include: ✔ 70 percent fewer harmful toxicants compared to cigarettes (Bekki et al., 2017). ✔ Less carbon monoxide exposure, reducing heart disease risks (Zhang et al., 2024). ✔ Improved lung health among former cigarette smokers who switch to HTPs (Szymanski et al., 2021).
If half of Japan’s smokers switched to HTPs, the country could see a drastic drop in smoking-related hospitalizations, easing pressure on healthcare facilities.
Comparison of Disease Prevalence Before and After HTP Adoption
| Disease | Current Cases | Projected Cases After HTP Adoption | Reduction (%) |
|---|---|---|---|
| COPD | 5.86 million | 4.86 million | -17% |
| Ischemic Heart Disease | 8.21 million | 5.80 million | -29% |
| Stroke | 26.05 million | 18.52 million | -29% |
| Lung Cancer | 7.79 million | 6.27 million | -20% |
By adopting HTPs, Japan could prevent over 12 million cases of smoking-related diseases each year, improving public health while reducing strain on hospitals (Mahlich & Kamae, 2024).
Potential Impact: Cost-Saving Potential in Japan’s Healthcare System
The Financial Burden of Smoking-Related Diseases
Smoking-related illnesses cost Japan trillions of yen each year in hospitalizations, medications, and long-term care (Mahlich & Kamae, 2024). Current annual healthcare expenses linked to smoking-related diseases are estimated at JPY 1.78 trillion (Ministry of Health, Labour and Welfare, 2022).
These costs include: ✔ Hospital admissions for respiratory and cardiovascular diseases. ✔ Medical treatments and rehabilitation for stroke and heart disease patients. ✔ Expensive cancer therapies for lung cancer cases.
With smoking-related diseases making up a significant portion of Japan’s healthcare spending, policymakers need effective solutions to cut costs and improve public health.
Potential Impact: Expected Healthcare Cost Savings Due to HTP Adoption
If Japan successfully transitions half of its smoking population to HTPs, it could save JPY 454 billion in healthcare costs annually (Mahlich & Kamae, 2024).
Projected Healthcare Cost Savings Due to HTP Adoption
| Disease | Current Costs (JPY) | Projected Costs After HTP Adoption | Savings (JPY) |
|---|---|---|---|
| COPD | 124.97 billion | 103.68 billion | 21.28 billion |
| Ischemic Heart Disease | 305.95 billion | 215.99 billion | 89.95 billion |
| Stroke | 853.84 billion | 607.16 billion | 246.67 billion |
| Lung Cancer | 492.87 billion | 396.74 billion | 96.13 billion |
These potential savings could allow Japan to redirect funds toward improving healthcare infrastructure, supporting medical research, and reducing patient costs (Mahlich & Kamae, 2024).
Potential Impact: Regional Differences in Health Benefits and Economic Impact
Why Some Prefectures Benefit More Than Others
Japan’s smoking rates vary by region, meaning that some prefectures will see greater benefits from widespread HTP adoption (Mahlich & Kamae, 2024).
Regions with the highest smoking rates include: ✔ Hokkaido (27% smoking prevalence) ✔ Tohoku (21%) ✔ Chugoku, Shikoku, and Kyushu (each at 21%)
These areas are most affected by smoking-related diseases and would experience the biggest reductions in healthcare costs if smokers transitioned to HTPs.
Healthcare Savings by Prefecture Due to HTP Adoption
| Region | Estimated Savings per 100,000 People (JPY) |
|---|---|
| Hokkaido (North) | 605 million |
| Kyushu (South) | 377 million |
Since these regions have higher smoking prevalence, switching to HTPs could lead to more noticeable public health improvements and significant financial savings (Mahlich & Kamae, 2024).
Potential Impact: Making Policy Changes to Get the Most Out of Heated Tobacco Products
Why Japan Needs Smarter Tobacco Tax Reforms
Japan taxes all tobacco products in the same way, whether they are traditional cigarettes or less harmful alternatives like heated tobacco products (HTPs). This one-size-fits-all approach doesn’t encourage smokers to switch to lower-risk options (Mahlich & Kamae, 2024).
In many countries, higher taxes on combustible cigarettes have successfully lowered smoking rates, but Japan hasn’t adjusted its policy to support harm reduction alternatives. A better tax system would: ✔ Increase taxes on regular cigarettes, discouraging their use. ✔ Lower taxes on HTPs, making them a more affordable choice for smokers looking to switch. ✔ Use taxation as a way to guide public health improvements, rather than just generating revenue (Djurdjevic et al., 2018).
Sweden successfully lowered tobacco-related diseases by reducing taxes on snus, a smokeless nicotine alternative, while keeping higher taxes on cigarettes. Sweden now has Europe’s lowest tobacco-related disease rate (Mahlich & Kamae, 2024). If Japan follows a similar taxation strategy for HTPs, it could speed up the decline in smoking prevalence while cutting healthcare costs.
Public-Private Partnerships Could Strengthen Harm Reduction
Tobacco control isn’t just a government issue—companies, healthcare professionals, and researchers should work together to promote harm reduction (Mahlich & Kamae, 2024).
Possible collaborations include: ✔ Educational campaigns to inform smokers about HTPs as a lower-risk option. ✔ Workplace policies like extra leave days for non-smokers, which some Japanese companies have already introduced (The Telegraph, 2017). ✔ Funding for medical studies to monitor the real-world effects of switching from cigarettes to HTPs.
Businesses have their own reason to reduce smoking rates—it leads to fewer sick days, higher productivity, and healthier employees. Companies and the government working together could make harm reduction strategies more effective and widely accepted (Mahlich & Kamae, 2024).
Japan Needs Ongoing Research and Data-Driven Policy Adjustments
Current research supports HTPs as a harm reduction tool, but long-term studies are still needed (Mahlich & Kamae, 2024). Policymakers should rely on scientific data to fine-tune regulations and ensure the best outcomes for public health.
Key research areas include: ✔ Tracking disease risk trends in people who switch to HTPs. ✔ Studying behavioral changes—how many smokers successfully transition to HTPs instead of cigarettes? ✔ Monitoring regional smoking rates to adjust public health strategies where they’re needed most.
By constantly improving policies based on new findings, Japan can build a smarter, evidence-based approach to tobacco control that balances health benefits and economic stability (Mahlich & Kamae, 2024).
7. Moving Toward a Smarter Tobacco Control Approach
Why Japan Should Support Harm Reduction Over Prohibition
Japan’s smoking-related healthcare costs continue to rise, and while traditional smoking cessation policies have had limited success, HTPs offer a realistic alternative for harm reduction (Mahlich & Kamae, 2024).
Switching to HTPs could: ✔ Prevent 12 million smoking-related disease cases annually. ✔ Save JPY 454 billion in healthcare costs. ✔ Ease strain on Japan’s hospitals and medical staff (Mahlich & Kamae, 2024).
Instead of trying to force people to quit smoking entirely, Japan should focus on helping smokers transition to lower-risk alternatives through taxation policies, public education, and research-backed strategies.
Balancing Public Health Goals with Economic Benefits
A strong tobacco harm-reduction policy needs to be practical—not just about banning cigarettes, but about offering safer alternatives that work for smokers who don’t want to quit (Mahlich & Kamae, 2024).
Smarter policies would: ✔ Encourage smokers to switch without making it financially difficult. ✔ Reduce healthcare spending by lowering smoking-related diseases. ✔ Ensure Japan’s long-term economic and healthcare sustainability.
Final Thoughts: Japan’s Next Steps in Tobacco Control
Rather than focusing only on restrictions, Japan should: ✔ Implement harm-reduction strategies that allow smokers to make better choices. ✔ Adjust tax policies so lower-risk alternatives become more accessible. ✔ Keep investing in research, updating policies based on long-term health data.
With a balanced and evidence-backed approach, Japan can reduce smoking prevalence, lower healthcare costs, and create a smarter public health strategy for the future (Mahlich & Kamae, 2024).
Reference
Mahlich, J., & Kamae, I. (2024). Switching from Cigarettes to Heated Tobacco Products in Japan—Potential Impact on Health Outcomes and Associated Health Care Costs. Healthcare, 12, 1937. https://doi.org/10.3390/healthcare12191937.
CC BY 4.0 License Statement
This article is licensed under the Creative Commons Attribution (CC BY) 4.0 license, which allows for unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.